Animal studies support that theory. GLP-1 drugs reduce inflammation in the brain and interfere with reward pathways linked to ...

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

Historically, managing type 2 diabetes in advanced chronic kidney disease (CKD) has been challenging due to a lack of therapies and increased risks for adverse events.

Semaglutide is marketed under the brand names, such as Ozempic, which is primarily prescribed for those with Type 2 diabetes, and Wegovy, which is commonly prescribed for weight loss. The drug mimics ...

Microglia replacement therapy helps treat people with a rare genetic condition called ALSP, suggesting the approach could ...

Scientists at UCSF combined advanced brain-network modeling, genetics, and imaging to reveal how tau protein travels through ...

GLP-1RAs were associated with improved quality of life and emotional eating behaviors among individuals with overweight and obesity.

Researchers have identified sequential diagnostic patterns that may enhance early detection and improve strategies for disease prevention. Researchers at UCLA Health have uncovered four distinct ...

The exact numbers depended on the type of medication patients took, but the risk of developing Alzheimer’s was up to 70 ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...

Boosting the brain’s sugar-clearing switch cuts toxic buildup and may explain why fasting looks good for memory.